Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

NCT04545554 PHASE1 COMPLETED Results posted

The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with Osteogenesis Imperfecta (OI).

Details

Lead sponsor	Amgen
Phase	PHASE1
Status	COMPLETED
Enrolment	25
Start date	Thu Jan 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Mar 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Osteogenesis Imperfecta

Interventions

• Romosozumab
• Calcium
• Vitamin D

Countries

Italy, Greece, Austria, Germany, Hungary, United States, Turkey (Türkiye), Spain